Physician profile
James Schack
NPI 1508313594
$11,143.50
in general payments reported to CMS, 2019-2025
40 companies · $1,835 in 2025
The $1,835 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $1,460 · 2021: $1,860 · 2022: $1,651 · 2023: $1,918 · 2024: $2,162 · 2025: $1,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,901 · Education: $13.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,901.18 |
| Education | $13.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,181.25 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $1,529.05 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,138.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $848.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $758.20 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $670.32 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $367.30 | 2022-2025 | |
| Amgen INC. | $290.22 | 2019-2025 | Otezla, Repatha, Evenity |
| Amarin Pharma, INC. | $277.31 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.30 | 2020-2025 | Xifaxan |
| Allergan, INC. | $238.69 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $229.14 | 2020-2024 | Trintellix |
| Mylan Specialty L.P. | $223.38 | 2023-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.75 | 2020-2024 | Jardiance, Tradjenta, Synjardy |
| Axsome Therapeutics, INC. | $191.61 | 2024-2025 | Auvelity |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $190.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $165.84 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $135.58 | 2020-2022 | |
| Dexcom, INC. | $128.48 | 2023-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $125.48 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $124.98 | 2022-2024 | Rexulti |
| Viatris Specialty LLC | $101.19 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $98.22 | 2021-2022 | |
| Verona Pharma, INC. | $85.88 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $82.16 | 2020-2024 | Gardasil 9, Vaqta, Vaxelis |
| Abbott Laboratories | $76.93 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.48 | 2025 | Caplyta |
| Medtronic, INC. | $48.49 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $43.34 | 2020-2025 | Eliquis |
| Xeris Pharmaceuticals, INC. | $42.65 | 2024 | Gvoke Hypopen |
| Astellas Pharma US INC | $40.44 | 2024-2025 | Veozah |
| Shire North American Group INC | $32.80 | 2019 | |
| Esperion Therapeutics, INC. | $26.87 | 2020-2025 | Nexletol |
| Alkermes, INC. | $26.58 | 2024 | Vivitrol |
| Ironshore Pharmaceuticals INC. | $22.62 | 2020 | |
| Insulet Corporation | $21.29 | 2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $14.85 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.59 | 2022 | |
| Adlon Therapeutics L.P. | $13.72 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Schack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.